


ARCC-4

Cat. No.:	HY-130492		
CAS No.:	1973403-00-7		
Molecular Formula:	C ₅₃ H ₅₆ F ₃ N ₇ O ₇ S ₂		
Molecular Weight:	1024.18		
Target:	PROTAC; Androgen Receptor		
Pathway:	PROTAC; Others		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 200 mg/mL (195.28 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	0.9764 mL	4.8820 mL	9.7639 mL	
		5 mM	0.1953 mL	0.9764 mL	1.9528 mL	
10 mM		0.0976 mL	0.4882 mL	0.9764 mL		
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 5 mg/mL (4.88 mM); Suspended solution; Need ultrasonic Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 5 mg/mL (4.88 mM); Suspended solution; Need ultrasonic Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 5 mg/mL (4.88 mM); Clear solution 					

BIOLOGICAL ACTIVITY

Description	ARCC-4 is a low-nanomolar androgen receptor (AR) degrader based on PROTAC, with a DC ₅₀ of 5 nM. ARCC-4 is an enzalutamide-based von Hippel-Lindau (VHL)-recruiting AR PROTAC and outperforms enzalutamide. ARCC-4 effectively degrades clinically relevant AR mutants associated with antiandrogen therapy ^[1] .
IC₅₀ & Target	VHL
In Vitro	ARCC-4 induces apoptosis and inhibiting proliferation of AR-amplified prostate cancer cells ^[1] .

ARCC-4 enhances protein-protein interactions between AR and VHL, thereby promoting the association of the trimeric complex^[1].

ARCC-4 (0.1-10,000 nM; 20 hours) potently degrades AR with a D₅₀ of 5 nM and D_{max} of over 95%^[1].

ARCC-4 (100 nM; 12 hours) shows near complete AR degradation (>98%) in prostate cancer cells^[1].

ARCC-4 selectively degrades AR via the proteasome but not PR-A or PR-B suppression^[1].

ARCC-4 shows efficacy against clinically relevant AR mutations^[1].

ARCC-4 maintains activity despite elevated androgen levels^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	VCaP cells
Concentration:	0.1 nM, 1 nM, 10 nM, 50 nM, 100 nM, 0.5µM, 1µM, 10 µM
Incubation Time:	20 hours
Result:	Potently degrades AR

REFERENCES

[1]. Salami J, et al. Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance. Commun Biol. 2018 Aug 2;1:100.

Caution: Product has not been fully validated for medical applications. For research use only.

India Contact:

Life Technologies (India) Pvt. Ltd.

306, Aggarwal City Mall, Opposite M2K Pitampura, Delhi – 110034 (INDIA). Ph: +91-11-42208000, 42208111, 42208222, Mobile: +91-9810521400, Fax: +91-11-42208444

Email: customerservice@lifetechindia.com Website: www.lifetechindia.com